Wednesday, April 10, 2019 @ 7:30 pm
MetrioPharm AG, a pharmaceutical development company, welcomes Barry Frankel as a new team member. Barry Frankel had already advised the company on strategic issues since 2018 and will assume the position of Senior Vice President Strategy and Business Development as of 2019. Barry Frankel had already advised the company on strategic issues since 2018 and will assume the position of Senior Vice President Strategy and Business Development as of 2019. He will be responsible for the future development strategy and Business Development. Negotiations with potential pharmaceutical partners will be a focus of his work.
Barry Frankel is the founder of Frankel Group LLC, a global life science strategy consulting firm with offices in New York NY, Cambridge MA and Tel Aviv. He served as a Director of Pfizer Pharmaceuticals and as a Senior Research Officer of Citibank Investment Management Group, responsible for investment recommendations in the life science industry. Barry Frankel was also a partner and president of SJ Weinstein Associates Inc, a healthcare advertising and marketing strategy firm.
Dr. Wolfgang Brysch, CEO of MetrioPharm AG: „Barry has worked in a senior position for large companies in the pharmaceutical industry and has an excellent network. We have come to know him as an experienced negotiator and outstanding strategist. Barry is the ideal addition to our team for the tasks ahead and we look forward to working with him”.
Barry Frankel: “When I met with the Board, with the CEO and with the senior management team, I was struck by their level of expertise and their level of commitment to the same mission to create a new business model in healthcare. The MetrioPharm team has a truly unique blend of professionalism and passion and I am happy to become a part of that.”